Erdafitinib usage and dosage

Erdafitinib(Erdafitinib) is an FGFR inhibitor. Erdafitinib blocks the activity of abnormal proteins that send reproduction signals to cancer cells, which helps slow or prevent the spread of cancer cells. Erdafitinib is approved by the U.S. FDA for the treatment of adults with locally advanced or metastatic urothelial carcinoma who have predisposing FGFR3 or FGFR2 genetic alterations and who have progressed during or after at least one platinum-containing chemotherapy.

Erdafitinib(Erdafitinib)The recommended dose in the instructions is 8mg orally once daily, on days 14 to 21, increasing to 9 based on serum phosphate levels and tolerance mgOral once daily until disease progression or unacceptable toxicity develops. Dose Reduction Plan for Adverse Reactions:

9mg dose regimen:The first dose is reduced to 8mg and the second dose is reduced to 6mg, the third dose was reduced to 5mg, the fourth dose was reduced to 4mg, and the fifth dose was reduced to discontinuation. 8mg dose regimen:First dose reduced to 6mg, the second dose was reduced to 5mg, the third dose was reduced to 4mg, and the fourth dose was reduced to discontinuation. No dose adjustment is recommended in patients with mild to moderate renal impairment. No dose adjustment is recommended in patients with mild to moderate hepatic impairment. Generic drugs are produced in Laos and Bangladesh, and each box costs about 2 more than 1,000. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.